TAK Overview
Upcoming Projects (TAK)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (TAK)
-
A Second Perspective: Discussing a4b7 integrin blocking in moderate to severe ulcerative colitis: Looking at 1st gen PTG-100 and MORF-057
Tickers: MORF, PTGX, TAK
Executed On: Feb 04, 2022 at 11:00 AM EST -
A discussion around a4b7 integrin blocking in moderate to severe ulcerative colitis: Looking at 1st gen PTG-100 and MORF-057
Tickers: MORF, PTGX, TAK
Executed On: Feb 01, 2022 at 02:00 PM EST -
A Second Look: What's the potential of NMTR's Vurolenatide in short bowel syndrome?
Tickers: NMTR, TAK
Executed On: Jan 06, 2022 at 01:30 PM EST -
What's the potential of NMTR's Vurolenatide in short bowel syndrome?
Tickers: NMTR, TAK
Executed On: Oct 19, 2021 at 12:30 PM EDT
Upcoming & Overdue Catalysts (TAK)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (TAK)
Strategic Initiatives (TAK)
-
Takeda Pharmaceutical Co(TAK) to sell eye drug Xiidra to Novartis AG(NVS)
Tickers: NVS, TAK
Announcement Date: May 08, 2019